Russia Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Russian diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Russia Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Russia Diabetes Drugs and Devices Market Size

Russia Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 4.00 %

Major Players

Russia Diabetes Drugs and Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Russia Diabetes Drugs and Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Russia Diabetes Drugs and Devices Market Analysis

The Russia Diabetes Drugs and Devices Market is expected to register a CAGR of greater than 4% during the forecast period.

A year into the COVID-19 pandemic, it caused premature deaths, especially among the elderly. Russia has the ninth-highest number of coronavirus cases in the world. Most people who die from COVID-19 are affected by having two or more chronic conditions in the same person. Several studies have confirmed that chronic conditions such as diabetes are associated with undesirable outcomes in COVID-19 patients. Diabetes drugs are designed to stabilize and control blood sugar levels in people with diabetes. Antidiabetic drugs have become potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the novel coronavirus disease (COVID-19) pandemic. Rapid increases in the incidence and prevalence of diabetes and healthcare costs indicate increased use of diabetes care products. According to Roscongress, Russia ranks fifth in the world in terms of the number of people with diabetes between the ages of 20 and 79. In addition, the death rate among people with diabetes increased by 22% during the COVID-19 pandemic.

An increasing rate of new diagnoses of type 1 and type 2 diabetes has been observed, mainly due to obesity, unhealthy diet, and lack of exercise. Rapid increases in the incidence and prevalence of diabetes and healthcare costs indicate increased use of diabetes care products. In May 2021, the World Health Assembly agreed to a resolution to strengthen diabetes prevention and control. Action is recommended in the following areas: Improving access to insulin. Facilitate consolidating and harmonising regulatory requirements for insulin and other drugs and healthcare products used to treat diabetes. Evaluate the feasibility and potential value of establishing a web-based tool for sharing information related to transparency in the diabetes drug and healthcare products market.

Therefore, owing to the aforementioned factors, the studied market is anticipated to grow over the analysis period.

Russia Diabetes Drugs and Devices Industry Overview

Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.

Russia Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
Russia Diabetes Drugs and Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Russia Diabetes Drugs and Devices Market News

  • February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction. It includes heart failure with mildly reduced and preserved ejection fraction.
  • February 2023: Medtronic PLC announced one-year data from the ADAPT study, the first multi-national randomized controlled study comparing the MiniMed 780G advanced hybrid closed loop system (AHCL) performance against multiple daily injections of insulin with an intermittently scanned CGM. The study was done in adults (18 years and older) who did not meet glycemic targets. At one year, significant improvements were reproduced in this cross-over group and sustained in those who started AHCL therapy at the start of the trial.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Restraints
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Consumers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products and Services
    • 4.3.5 Intensity of Competitive Rivalry

5. Market Segmentation (Market Size by Value - USD)

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Russia Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections, such as insulin. The Russia diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current undefined size?

The undefined is projected to register a CAGR of greater than 4% during the forecast period (2025-2030)

Who are the key players in undefined?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.

What years does this undefined cover?

The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Russia Diabetes Drugs and Devices Industry Report

Statistics for the 2025 Russia Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Russia Diabetes Drugs and Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.